A Multicenter, Randomized, Double-Blind Phase 3 Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With ER(+), HER2 (-) Advanced Breast Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind Phase 3 Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With ER(+), HER2 (-) Advanced Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PALOMA-4
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2017 Planned End Date changed from 30 Apr 2018 to 31 Dec 2022.
    • 18 May 2017 Planned primary completion date changed from 30 Apr 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top